NEW YORK (360Dx) – Biofortuna, a UK-based contract in vitro diagnostics development, freeze drying, and stabilization services provider, announced this week a new investment into and an expansion of its IVD service portfolio. The expansion will allow the firm to place a greater focus on immunoassay design, development, and manufacturing.
"The success and growth of current projects has fueled the desire to increase our immunoassay offering," Simon Douglas, Biofortuna CEO said in a statement. "This expansion will allow for large-scale manufacturing of ELISA-based kits to meet our customers’ growing needs," he said.
The expansion includes a £250,000 ($313,150) investment in equipment and infrastructure to ramp up production capabilities, a Biofortuna representative confirmed.
The increased focus on immunoassay products will complement Biofortuna's molecular IVD services that include ISO 13485 accredited and FDA registered contract research, lyophilization, air-drying, manufacturing, dispensing and kitting of diagnostic products, the firm said.